These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24350848)

  • 1. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L; Jiang S
    ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.
    Tan JJ; Ma XT; Liu C; Zhang XY; Wang CX
    Curr Pharm Des; 2013; 19(10):1810-7. PubMed ID: 23092283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
    Mostashari Rad T; Saghaie L; Fassihi A
    Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
    He Y
    Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of small molecule HIV-1 fusion inhibitors: linking biology to chemistry.
    Miyamoto F; Kodama EN
    Curr Pharm Des; 2013; 19(10):1827-34. PubMed ID: 23092276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
    Lu L; Yu F; Cai L; Debnath AK; Jiang S
    Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.
    Zhou G; Chu S
    Curr Pharm Des; 2013; 19(10):1818-26. PubMed ID: 23092284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
    Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
    Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
    He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
    Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
    Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
    Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
    PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.